Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | PDXK | O00764 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxamine SCHEMBL8904115 | 0.98 | LMNA (0.82) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL30408 | 0.92 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL11469627 | 0.91 | LMNA (0.75) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL48103 | 0.90 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL561421 | 0.90 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL7749395 | 0.90 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxal SCHEMBL27864030 | 0.89 | KDM4E (0.70) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL9291549 | 0.89 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL3555546 | 0.89 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxine SCHEMBL29004449 | 0.89 | KDM4E (0.83) | LMNAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 913 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081007-A | Extraction method and application of lysimachia foenum-graecum volatile oil | — | 2026-05-26 | — | — | CN | claimed |
| CN-119792284-A | Application of vitamin B6 in preparing medicine for preventing and/or treating NLRP6 inflammation small body overactive state diseases | 中国科学技术大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119285924-A | Nicotinic acid modified pyridoxamine polyether polyol and preparation method thereof | 山东一诺威新材料有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119082097-A | Immobilized L-cysteine synthetase, and preparation method and application thereof | 黑龙江新和成生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-117789993-B | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-06-11 | — | — | CN | claimed |
| US-20240180891-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2024-06-06 | — | — | US | claimed |
| CN-118021982-A | Pharmaceutical composition containing mineralocorticoid receptor antagonist and B vitamins | 深圳奥萨制药有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117899078-A | Application of vitamin B6 in preparation of medicines for preventing and/or treating NLRP6 inflammation small body related diseases | 中国科学技术大学 | 2024-04-19 | — | — | CN | claimed |
| CN-117789993-A | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-03-29 | — | — | CN | claimed |
| CN-114540455-B | Process for preparing chiral beta-amino acid derivatives | 浙江医药股份有限公司新昌制药厂 | 2024-01-30 | — | — | CN | claimed |
| EP-0282696-B1 | USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND TREATMENT OF HYPERLIPEMIA AND ATHEROSCLEROSIS | STEIGERWALD ARZNEIMITTELWERK GMBH (DE) | 1992-11-11 | — | — | EP | claimed |
| US-5160725-A | Contrast agent for diagnostic imaging, polyethylene glycol phosphates and carboxylates as stabilizers | SILICA GEL GESELLSCHAFT MBH ADSORPTIONS-TECHNIK, APPARATEBAU (DE) | 1992-11-03 | — | — | US | claimed |
| EP-0495270-A1 | Azaribine composition | Drell, William, Dr. (US) | 1992-07-22 | — | — | EP | claimed |
| EP-0284549-B1 | MAGNETIC FLUID COMPOSITIONS | Silica Gel Ges.mbH Absorptionstechnik, Apparatebau (DE) | 1992-07-15 | — | — | EP | claimed |
| WO-1992001781-A1 | ANTIBODY-MEDIATED COFACTOR-DRIVEN REACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-02-06 | — | — | WO | claimed |
| US-5023083-A | Azarbine composition | DRELL WILLIAM (US) | 1991-06-11 | — | — | US | claimed |
| EP-0379936-A2 | Pyridoxal for use in enzyme deficiencies, and a diagnostic kit for their diagnosis | VESTA MEDICINES (PROPRIETARY) LIMITED (ZA) | 1990-08-01 | — | — | EP | claimed |
| EP-0284549-A2 | Magnetic fluid compositions | Silica Gel Ges.mbH Absorptionstechnik, Apparatebau (DE) | 1988-09-28 | — | — | EP | claimed |
| EP-0282696-A2 | Use of pyridoxine derivatives in the prophylaxis and treatment of hyperlipemia and atherosclerosis | STEIGERWALD ARZNEIMITTELWERK GMBH (DE) | 1988-09-21 | — | — | EP | claimed |
| EP-0106813-A2 | Pharmaceutical utilisation of 3-indolpyruvic acid | POLIFARMA S.p.A. (IT) | 1984-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180891-A1 | SYNERGISTIC MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR INDUCING WEIGHT LOSS AND THE TREATMENT OF DIABETIC PATHOLOGIES | PDXK, PLPBP, GLS | LMNA 823/4885KDM4E 1454/4885ALDH1A1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.